U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07400575) titled 'Anlotinib in Cross-line Treatment of NSCLC and SCLC' on Jan. 27.
Brief Summary: Previous studies on bevacizumab in colorectal and ovarian cancers have demonstrated that continued anti-angiogenic therapy after disease progression can still provide clinical benefits. As a typical multi-targeted anti-angiogenic tyrosine kinase inhibitor, anlotinib hydrochloride has been approved in China for second-line or later treatment of advanced soft tissue sarcoma, where it has also shown significant potential. Retrospective studies have indicated the effectiveness of anlotinib in cross-line treatment for sarcoma. However, there is a lack of mult...